Last reviewed · How we verify

Guangzhou JOYO Pharma Co., Ltd — Portfolio Competitive Intelligence Brief

Guangzhou JOYO Pharma Co., Ltd pipeline: 0 marketed, 0 filed, 2 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 4 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Cross-over to JYP0322 Cross-over to JYP0322 phase 3 SGLT2 inhibitor SGLT2 Diabetes
JYP0322 tablets JYP0322 tablets phase 3 SGLT2 inhibitor SGLT2 Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 2 shared drug classes
  2. Teva Branded Pharmaceutical Products R&D, Inc. · 2 shared drug classes
  3. GlaxoSmithKline · 2 shared drug classes
  4. AJU Pharm Co., Ltd. · 1 shared drug class
  5. AceLink Therapeutics, Inc. · 1 shared drug class
  6. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  7. Abbott · 1 shared drug class
  8. Aciex Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Guangzhou JOYO Pharma Co., Ltd:

Cite this brief

Drug Landscape (2026). Guangzhou JOYO Pharma Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/guangzhou-joyo-pharma-co-ltd. Accessed 2026-05-16.

Related